EVERSANA, a provider of commercial services to the life science industry, agreed to acquire Cornerstone Research Group, a global health economic and market access research company supporting pharmaceutical and medical device companies. Financial terms were not disclosed. "Pharmaceutical companies face strong pressures to quickly assess and quantify both the direct and indirect value of their in-market products and development pipeline. By adding a strong health economics and outcomes capability to our integrated commercial platform, we can now conceptualize, deliver and measure value at every stage of the product lifecycle from clinical trials to ongoing patient adherence. The Cornerstone Research Group team brings tremendous expertise that will deliver immediate value to our clients worldwide, and we're thrilled to have them on board," Jim Lang, CEO.